Payment overview · 2025
General Payments
$1,624.64
73 reported records · 23 companies
Healthcare provider profile · identity verified
Mario Wassel, MD
Allopathic & Osteopathic Physicians|Family Medicine · BARNEVELD, NY · NPI 1922561273
Verified facts
What the public records show
CMS Open Payments records show Mario Wassel, MD received $1,624.64 in general payments during 2025 across 73 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $459.38 | 28.3% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $231.99 | 14.3% | 14 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $96.19 | 5.9% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $83.11 | 5.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $75.87 | 4.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.54 | 4.3% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $65.84 | 4.0% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $63.65 | 3.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.31 | 3.7% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.35 | 3.1% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $49.61 | 3.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $49.12 | 3.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.86 | 2.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.43 | 2.2% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $31.04 | 1.9% | 2 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $27.18 | 1.7% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $21.86 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.77 | 1.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.31 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.59 | 1.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.15 | 1.2% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.80 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.69 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,624.64 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $264.33 | 12 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.77 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $96.19 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $92.17 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $86.74 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $83.11 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $68.37 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $65.84 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $63.65 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $50.68 | 3 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $50.35 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $49.61 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $49.12 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $47.81 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.89 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.43 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.93 | 2 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 93 |
| Lisinopril | Lisinopril | 274 | 79 |
| Losartan Potassium | Losartan Potassium | 271 | 89 |
| Metformin Hcl | Metformin Hcl | 262 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 87 |
| Furosemide | Furosemide | 224 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 68 |
| Omeprazole | Omeprazole | 201 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 75 |
| Simvastatin | Simvastatin | 197 | 50 |
| Gabapentin | Gabapentin | 158 | 48 |
| Potassium Chloride | Potassium Chloride | 153 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 44 |
| Eliquis | Apixaban | 132 | 31 |
| Alprazolam | Alprazolam | 128 | 26 |
| Ozempic | Semaglutide | 128 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 53 |
| Jardiance | Empagliflozin | 122 | 27 |
| Famotidine | Famotidine | 120 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 34 |
| Allopurinol | Allopurinol | 102 | 41 |
| Sertraline Hcl | Sertraline Hcl | 99 | 29 |
| Meloxicam | Meloxicam | 96 | 24 |
| Ezetimibe | Ezetimibe | 93 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 35 |
| Carvedilol | Carvedilol | 88 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 30 |
| Prednisone | Prednisone | 81 | 53 |
| Metformin Hcl Er | Metformin Hcl | 66 | 23 |
| Montelukast Sodium | Montelukast Sodium | 65 | 21 |
| Mirtazapine | Mirtazapine | 63 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 17 |
| Donepezil Hcl | Donepezil Hcl | 58 | 17 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Xarelto | Rivaroxaban | 54 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 18 |
| Trazodone Hcl | Trazodone Hcl | 51 | 14 |
| Ramipril | Ramipril | 50 | 18 |
| Azithromycin | Azithromycin | 48 | 37 |
| Farxiga | Dapagliflozin Propanediol | 48 | 16 |
| Tramadol Hcl | Tramadol Hcl | 48 | 19 |
| Synthroid | Levothyroxine Sodium | 47 | 13 |
| Glimepiride | Glimepiride | 46 | 16 |
| Nystatin | Nystatin | 45 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 40 | 14 |
| Irbesartan | Irbesartan | 39 | 12 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Atenolol | Atenolol | 37 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Torsemide | Torsemide | 35 | 15 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 21 |
| Tradjenta | Linagliptin | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 14 |
| Kerendia | Finerenone | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 26 |
| Spironolactone | Spironolactone | 29 | 11 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 28 | 27 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 12 |
| Alendronate Sodium | Alendronate Sodium | 27 | 13 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Cephalexin | Cephalexin | 21 | 14 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Fosinopril Sodium | Fosinopril Sodium | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 18 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,624.64 · 73 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACTHAR, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, FASENRA, FREESTYLE LIBRE 3, FUROSCIX, Fabhalta, Flector, GVOKE HYPOPEN, INSPIRE, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, Licart, MOUNJARO, Ohtuvayre, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REPATHA, SMARTVEST, TAVNEOS, Tirosint, UPLIZNA, VOYXACT, Vafseo, WAKIX, WATCHMAN FLX, Xhance, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error